Study number 8543-771
Dates
Jun 30 2025-Sep 23 2025
Location
Dallas, Texas
Age
18-64
Gender
Both Males and Females
Smoker
Yes
Compensation
$13,324
Group
2e
This is a research study for an investigational drug being developed as a supplement to a reduced calorie diet and increased physical activity for long-term weight management. Tirzepatide is an injectable prescription drug that has been approved by the FDA for chronic weight management, in addition to diet, exercise, and oral (by mouth) medications. The use of tirzepatide in combination with the study drug in this study is investigational.
Fortrea Dallas, TX is recruiting for:
-Healthy Males and Females, age 18-64
-Body Mass Index between 22-30
-Study involves 1 stay of 6 nights & 9 follow-up visits*
-Compensation up to $13,324 may be provided for time and participation
-Refer a friend to receive $350 per qualified referral
*Additional inpatient or outpatient visit may be required.
2e:
Check-in: Jun 30
Check-out: Jul 6
OPV: Jul 8, 11, 15, 22, 29, Aug 12, 26, Sep 9, 23